Lithium as adjuvant to radioiodine therapy in differentiated thyroid carcinoma:: clinical and in vitro studies

被引:45
|
作者
Liu, Y. Y.
van der Pluijm, G.
Karperien, M.
Stokkel, M. P. M.
Pereira, A. M.
Morreau, J.
Kievit, J.
Romijn, J. A.
Smit, J. W. A.
机构
[1] Leiden Univ, Med Ctr, Dept Endocrinol, NL-2300 RC Leiden, Netherlands
[2] Leiden Univ, Med Ctr, Dept Nucl Med, NL-2300 RC Leiden, Netherlands
[3] Leiden Univ, Med Ctr, Dept Pathol, NL-2300 RC Leiden, Netherlands
[4] Leiden Univ, Med Ctr, Dept Surg, NL-2300 RC Leiden, Netherlands
关键词
D O I
10.1111/j.1365-2265.2006.02515.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective Lithium has been reported to increase radioactive iodine (RaI) doses in benign thyroid disease and in differentiated thyroid carcinoma (DTC). It is not known whether lithium influences the outcome of RaI therapy in DTC. We therefore studied the clinical effects of RaI without and with lithium carbonate in patients with proven metastatic DTC. Controversy also exists on the mechanism by which lithium increases RaI dose in DTC. We performed an in vitro study specifically aimed at examining the effects of lithium on the sodium iodide symporter (NIS). Design In a clinical study, 12 patients were selected with metastases of DTC who had received previous RaI therapy without lithium (control) that had not influenced turnout progression, despite RaI accumulation in metastases. The patients received 1200 mg lithium carbonate/day followed by 6000 MBq RaI. Outcome parameters were RaI uptake, serum thyroglobulin (Tg) levels and radiological dimensions of metastases compared between RaI with lithium and control. In an in vitro study, iodide uptake was studied in the benign rat thyroid cell line FRTL-5, in the polarized non-thyroid MDCK cell line, stably transfected with human sodium iodide symporter (hNIS) to study the effects of lithium on NIS in a non-thyroid background, and the human follicular thyroid carcinoma cell line FTC133-hNIS to study lithium effects in a background of DTC. Lithium chloride (LiCl) was added in concentrations up to 2 mm for 0-48 h. Both steady-state iodide uptake (30 min) and initial rate (2 min) were studied using a specific activity of 100 mCi/mmol I, the latter experiment to determine lithium effects on substrate dependency. Iodide efflux studies were performed as well. Results Despite an increased uptake of RaI in seven patients, no beneficial effect of RaI with lithium was observed on the clinical course as assessed by serum Tg measurements and radiographically. In the in vitro studies, no effects of LiCl on iodide uptake or efflux were observed.
引用
收藏
页码:617 / 624
页数:8
相关论文
共 50 条
  • [1] Editorial: Optimizing the outcomes of adjuvant radioiodine therapy in differentiated thyroid carcinoma
    Sherman, SI
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (09): : 4059 - 4062
  • [2] RADIOIODINE THERAPY FOR DIFFERENTIATED THYROID-CARCINOMA
    CONNOR, CS
    THOMAS, JH
    ROBINSON, RG
    PRESTON, DF
    HERMRECK, AS
    [J]. AMERICAN JOURNAL OF SURGERY, 1988, 156 (06): : 519 - 521
  • [3] Differentiated thyroid carcinoma referred for radioiodine therapy
    Al-Balawi, IA
    Meir, HM
    Yousef, MK
    Nayel, HA
    Al-Mobarak, MF
    [J]. SAUDI MEDICAL JOURNAL, 2001, 22 (06) : 497 - 503
  • [4] RADIOIODINE THERAPY IN DIFFERENTIATED THYROID-CARCINOMA
    EILLES, C
    [J]. NUKLEARMEDIZINER, 1991, 14 (01): : 19 - 25
  • [5] The ablative radioiodine therapy of differentiated thyroid carcinoma
    Rottenburger, Christof
    Lutz, Thomas
    [J]. THERAPEUTISCHE UMSCHAU, 2020, 77 (09) : 427 - 431
  • [6] Guidelines on radioiodine therapy for differentiated thyroid carcinoma -: Impact on clinical practice
    Biermann, M
    Pixberg, MK
    Dörr, U
    Dietlein, M
    Schlemmer, H
    Grimm, J
    Zajic, T
    Nestle, U
    Ladner, S
    Sepehr-Rezai, S
    Rosenbaum, S
    Puskás, C
    Fostitsch, P
    Heinecke, A
    Schuck, A
    Willich, N
    Schmid, KW
    Dralle, H
    Schober, O
    [J]. NUKLEARMEDIZIN-NUCLEAR MEDICINE, 2005, 44 (06): : 229 - +
  • [7] Radioiodine adjuvant therapy in differentiated thyroid cancer: An update and reconsideration
    Sun, Yu-qing
    Sun, Di
    Zhang, Xin
    Zhang, Ying-qiang
    Lin, Yan-song
    [J]. FRONTIERS IN ENDOCRINOLOGY, 2022, 13
  • [8] Lithium as adjuvant to radioiodine therapy in thyroid cancer treatment
    Stokkel, M. P.
    Liu, Y. Y.
    Pereira, A. M.
    Romijn, H. A.
    Smit, J. W. A.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2006, 33 : S354 - S354
  • [9] Radioiodine therapy of differentiated thyroid carcinoma and recurrences of disease
    Stefanovic, L.
    Mihailovic, J.
    Malesevic, M.
    Nikoletic, K.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2006, 33 : S331 - S331
  • [10] Radioiodine therapy for well-differentiated thyroid carcinoma
    Schicha, H
    Dietlein, M
    [J]. ZENTRALBLATT FUR CHIRURGIE, 1997, 122 (04): : 266 - 273